Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation
- 291 Downloads
Allogeneic haematopoietic stem cell transplantation (HSCT) is a proven treatment for patients with haematological malignancies. In this retrospective analysis, the impact of donor matching on outcome of unrelated HSCT was analysed in patients transplanted at the University of Leipzig.
From 2000 to 2009, 206 patients were transplanted from unrelated donors, of which 51 were mismatched (39 in 1 and 12 in ≥2 HLA-antigens), using peripheral blood or bone marrow grafts after total body irradiation and cyclophosphamide or busulfan and cyclophosphamide preparative regimens in combination with ATG. For graft-versus-host disease (GvHD) prophylaxis cyclosporine and MTX were administered.
After a median follow-up of 49 months, outcome at 5 years in recipients of HLA-identical grafts was comparable to that of patients transplanted from HLA-incompatible donors with an overall survival (OS) of 52 % (95 % CI 43–61) versus 48 % (95 % CI 34–63), respectively (p = 0.48). Results were also comparable for event-free survival at 5 years [47 % (95 % CI 38–56) vs. 39 % (95 % CI 25–54); p = 0.44], relapse incidence (RI) [29 % (95 % CI 20–38) vs. 41 (95 % CI 25–57); p = 0.22] and non-relapse mortality [24 % (95 % CI 16–33) vs. 20 % (95 % CI 8–33); p = 0.84] in the matched versus mismatched groups. Incidence of acute and chronic GvHD was similar in both groups. Advanced disease (p = 0.02) and low-resolution typing (p = 0.04) are risk factors for OS and RI in univariate and multivariate analysis.
Donors with one antigen mismatch are an acceptable option for patients with malignant disease for whom no fully matched donor is available.
KeywordsAllogeneic stem cell transplantation Unrelated donors HLA-antigen mismatch Graft-versus-host disease Relapse
Compliance with Ethical Standards
Conflict of interest
All authors declare no conflict of interest.
Informed consent was obtained from all individual patients included in this study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97(10):2957–2961CrossRefPubMedGoogle Scholar
- Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M, Burchardt A et al (2005) Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transpl 35(10):1011–1018CrossRefGoogle Scholar
- Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104(7):1923–1930CrossRefPubMedGoogle Scholar
- Greinix HT, Faé I, Schneider B, Rosenmayr A, Mitterschiffthaler A, Pelzmann B et al (2005) Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transpl 35(1):57–62CrossRefGoogle Scholar
- Kroeger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al (2009) HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transpl 15(4):454–462CrossRefGoogle Scholar
- Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Durken M et al (2001) Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 80(4):209–215CrossRefPubMedGoogle Scholar
- Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K et al (2007) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transpl 13(8):965–974CrossRefGoogle Scholar
- Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065–3073CrossRefPubMedGoogle Scholar
- Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al (2002) The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99(11):4200–4206CrossRefPubMedGoogle Scholar
- Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS et al (1995) The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86(3):1228–1234PubMedGoogle Scholar
- National Marrow Donor Program (1992) Donor center manual of operations. Minneapolis, Chapter 6 (p 11)Google Scholar
- Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier B et al (2003) Low-dose total body irradiation (TBI) and fludarabine follwed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629CrossRefPubMedGoogle Scholar
- Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB et al (2001a) Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98(10):2922–2929CrossRefPubMedGoogle Scholar
- Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl 15(6):825–828Google Scholar
- Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al (2007) Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25(27):4246–4254CrossRefPubMedGoogle Scholar
- Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P et al (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73:1729–1734PubMedGoogle Scholar